Novel oral anticoagulants and reversal agents: Considerations for clinical development.

MLA

Sarich, Troy C., et al. “Novel Oral Anticoagulants and Reversal Agents: Considerations for Clinical Development.” American Heart Journal, vol. 169, no. 6, June 2015, pp. 751–57. EBSCOhost, https://doi.org/10.1016/j.ahj.2015.03.010.

APA

Sarich, T. C., Seltzer, J. H., Berkowitz, S. D., Costin’, J., Curnutte, J. T., Gibson, C. M., Hoffman, M., Kaminskas, E., Krucoff, M. W., Levy, J. H., Mintz, P. D., Reilly, P. A., Sager, P. T., Singer, D. E., Stockbridge, N., Weitz, J. I., & Kowey, P. R. (2015). Novel oral anticoagulants and reversal agents: Considerations for clinical development. American Heart Journal, 169(6), 751–757. https://doi.org/10.1016/j.ahj.2015.03.010

Chicago

Sarich, Troy C., Jonathan H. Seltzer, Scott D. Berkowitz, James Costin’, John T. Curnutte, C. Michael Gibson, Maureane Hoffman, et al. 2015. “Novel Oral Anticoagulants and Reversal Agents: Considerations for Clinical Development.” American Heart Journal 169 (6): 751–57. doi:10.1016/j.ahj.2015.03.010.